Irinotecano Aurovitas (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside tumor cells to the active metabolite SN‑38, which inhibits topoisomerase I. This enzyme normally relaxes DNA during replication; its inhibition leads to persistent single‑strand breaks, triggering DNA damage and ultimately causing cancer cell death.

The dosing regimen for Irinotecano Aurovitas is individualized. A qualified prescriber determines the dose, infusion schedule, and any dose modifications based on the patient’s clinical condition, body surface area, and organ function.

There are limited data on the use of irinotecan in pregnant or nursing individuals. Because the drug can cross the placenta and is excreted in breast milk, it is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant.

To place an order, submit an enquiry on the Irinotecano Aurovitas product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a mechanism distinct from oxaliplatin (a platinum compound) or fluoropyrimidines. In combination regimens, irinotecan provides synergistic activity and is often used when tumors are resistant to or have progressed after oxaliplatin‑based therapy.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Prior to use, it is reconstituted according to the manufacturer’s instructions and administered under aseptic conditions.

Irinotecano Aurovitas is given by intravenous infusion. The reconstituted solution is infused over a specified period, typically ranging from 30 minutes to several hours, depending on the treatment protocol and patient tolerance.

The most critical adverse events include severe neutropenia with fever, life‑threatening diarrhea or colitis, and rare but serious allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential to reduce morbidity.

Patients with known hypersensitivity to irinotecan or any component of the formulation should avoid the product. Caution is also advised for individuals with severe hepatic impairment, uncontrolled infections, or those who are pregnant or breastfeeding unless the therapeutic benefit justifies the risk.